



DIRECT TREATMENT OF
INFLUENZA WITH VACCINES

For Prophylactic and Therapeutic Use.

INFLUENZA VACCINE

No. 1—First Dose.	
B. Influenza	... 30 millions
Pneumococcus	... 100 millions
Streptococcus	... 40 millions

No. 2.—2nd Dose.

B. Influenza	... 60 millions
Pneumococcus	... 200 millions
Streptococcus	... 80 millions

ANTI-CATARRH VACCINE

Prophylactic (A).	
Pneumococcus	... 25 millions
Pneumobacillus	... 50 millions
Micro Catarrhalis	... 250 millions
B. Influenza	... 250 millions
Diphtheroid (Oral)	... 50 millions
Staphylococcus ,	... 400 millions
Streptococcus ,	... 10 millions

Prophylactic (B).

Pneumococcus	... 50 millions
Pneumobacillus	... 100 millions
Micro Catarrhalis	... 500 millions
B. Influenza	... 500 millions
Diphtheroid (Oral)	... 100 millions
Staphylococcus ,	... 800 millions
Streptococcus ,	... 20 millions

THE VACCINE FOR COLDS

Curative (A).

Pneumococcus	... 25 millions
Pneumobacillus	... 25 millions
Micro Catarrhalis	... 100 millions
B. Influenza	... 250 millions
Diphtheroid (Oral)	... 25 millions
Staphylococcus ,	... 250 millions
Streptococcus ,	... 5 millions

Curative (B).

Pneumococcus	... 50 millions
Pneumobacillus	... 50 millions
Micro Catarrhalis	... 200 millions
B. Influenza	... 500 millions
Diphtheroid (Oral)	... 50 millions
Staphylococcus ,	... 500 millions
Streptococcus ,	... 10 millions

Prepared by

The Research Laboratory of the Royal College of Physicians, Edinburgh.

Issued by and full particulars from

DUNCAN, FLOCKHART & CO.,
EDINBURGH & LONDON.

LONDON : 155/7, FARRINGDON ROAD, E.C. 1.